Evaluating Palliative Chemotherapy Claims for Breast Cancer in India
Author Information
Author(s): Bauhoff Sebastian, Sengar Manju, Pramesh C. S., Dhiman Anamika, Mehndiratta Abha
Primary Institution: Harvard TH Chan School of Public Health
Hypothesis
Are the claims for the unlisted palliative care package for breast cancer patients appropriate according to clinical guidelines?
Conclusion
Most claims for the palliative chemotherapy package were found to be inappropriately selected due to insufficient documentation.
Supporting Evidence
- Only 33% of claims were selected according to clinical guidelines.
- 60% of claims were deemed inappropriate due to lack of documentation.
- The public hospital had a higher rate of appropriate selections compared to the private hospital.
- Many claims lacked necessary documentation to assess appropriateness.
- Claims for palliative treatment accounted for a significant share of oncology claims.
Takeaway
The study looked at how hospitals in India file claims for breast cancer treatment, and found that many of them did it wrong, which could hurt patients.
Methodology
A clinical audit was conducted by reviewing claims and supporting documents for 50 breast cancer patients from one public and one private hospital.
Potential Biases
Potential coding errors and variations in reporting practices could affect the findings.
Limitations
The sample may not be representative of all hospitals, and there may be missing documentation affecting the assessment.
Participant Demographics
All participants were female breast cancer patients receiving palliative care.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website